(Q47583241)

4 February 2018

title

Nebulised salbutamol with and without ipratropium bromide in acute airflow obstruction (English)

1 reference

4 February 2018

1 reference

B R O'Driscoll

1

1 reference

4 February 2018

R J Taylor

2

1 reference

4 February 2018

M G Horsley

3

1 reference

4 February 2018

D K Chambers

4

1 reference

4 February 2018

A Bernstein

5

1 reference

4 February 2018

language of work or name

English

0 references

publication date

1 June 1989

1 reference

4 February 2018

published in

The Lancet

1 reference

4 February 2018

volume

1

1 reference

4 February 2018

issue

8652

1 reference

4 February 2018

page(s)

1418-1420

1 reference

4 February 2018

Emergency use of nebulised bronchodilator drugs in British hospitals

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2889%2990126-8

7 January 2021

Ipratropium bromide in acute asthma.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2889%2990126-8

7 January 2021

A place for ipratropium bromide in the treatment of severe acute asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2889%2990126-8

7 January 2021

Nebulized ipratropium bromide in the treatment of acute asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2889%2990126-8

7 January 2021

Combined salbutamol and ipratropium bromide by inhalation in the treatment of severe acute asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2889%2990126-8

7 January 2021

Should ipratropium bromide be added to beta-agonists in treatment of acute severe asthma?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2889%2990126-8

7 January 2021

Nebulized anticholinergic and sympathomimetic treatment of asthma and chronic obstructive airways disease in the emergency room

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2889%2990126-8

7 January 2021

Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, November 1986

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2889%2990126-8

7 January 2021

Bronchoconstrictor properties of preservatives in ipratropium bromide (Atrovent) nebuliser solution

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2889%2990126-8

7 January 2021

Assessment of the clinical usefulness of nebulised ipratropium bromide in patients with chronic airflow limitation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2889%2990126-8

7 January 2021

Anticholinergic, Antimuscarinic Bronchodilators1,2

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2889%2990126-8

7 January 2021

Role of the parasympathetic system in airway obstruction due to emphysema

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2889%2990126-8

7 January 2021

Intravenous beta agonist in severe acute asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2889%2990126-8

7 January 2021

10.1016/S0140-6736(89)90126-8

Identifiers

DOI

1 reference

4 February 2018

1 reference

4 February 2018